Prospective evaluation of clinical and economic outcomes associated with treatment of serious infections due to gram-positive cocci

Elizabeth D. Hermsen, Sara S. Shull, Isaac F. Mitropoulos, Susan E. Puumala, Mark Edmund Rupp

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Comparative data are needed to define the use of agents to treat serious gram-positive cocci infections. This prospective, open-label, observational cohort study included adults receiving daptomycin, linezolid, vancomycin, or oxacillin/cefazolin for complicated skin and skin structure infections, bacteremia, endocarditis, or osteomyelitis. Primary outcome was clinical response at 180 days. Secondary outcomes included response at the end of therapy, antibiotic switch due to failure, length of stay (LOS), LOS after antibiotic start, mortality, infection-related readmission, and antibiotic and hospitalization costs. One hundred seventeen patients were evaluated for complicated skin and skin structure infections (n= 37), bacteremia (n = 49), endocarditis (n = 10), and osteomyelitis (n = 21). Daptomycin (P = 0.008) and linezolid (P = 0.02) were used more often as second-line therapy. No significant differences were found in outcomes except LOS (P = 0.05), and hospitalization costs (P = 0.004) were higher with linezolid; antibiotic costs were higher for linezolid (P = 0.001) and daptomycin (P = 0.03). Response rates were similar for the study drugs, although daptomycin and linezolid were used as second-line therapy and associated with higher drug costs.

Original languageEnglish (US)
Pages (from-to)17-21
Number of pages5
JournalInfectious Diseases in Clinical Practice
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Linezolid
Gram-Positive Cocci
Daptomycin
Cost-Benefit Analysis
Anti-Bacterial Agents
Infection
Length of Stay
Skin
Osteomyelitis
Bacteremia
Endocarditis
Costs and Cost Analysis
Hospitalization
Therapeutics
Cefazolin
Oxacillin
Drug Costs
Vancomycin
Observational Studies
Cohort Studies

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Prospective evaluation of clinical and economic outcomes associated with treatment of serious infections due to gram-positive cocci. / Hermsen, Elizabeth D.; Shull, Sara S.; Mitropoulos, Isaac F.; Puumala, Susan E.; Rupp, Mark Edmund.

In: Infectious Diseases in Clinical Practice, Vol. 17, No. 1, 01.01.2009, p. 17-21.

Research output: Contribution to journalArticle

@article{4f7764e61eff4a73bf46da05eb6c5d7d,
title = "Prospective evaluation of clinical and economic outcomes associated with treatment of serious infections due to gram-positive cocci",
abstract = "Comparative data are needed to define the use of agents to treat serious gram-positive cocci infections. This prospective, open-label, observational cohort study included adults receiving daptomycin, linezolid, vancomycin, or oxacillin/cefazolin for complicated skin and skin structure infections, bacteremia, endocarditis, or osteomyelitis. Primary outcome was clinical response at 180 days. Secondary outcomes included response at the end of therapy, antibiotic switch due to failure, length of stay (LOS), LOS after antibiotic start, mortality, infection-related readmission, and antibiotic and hospitalization costs. One hundred seventeen patients were evaluated for complicated skin and skin structure infections (n= 37), bacteremia (n = 49), endocarditis (n = 10), and osteomyelitis (n = 21). Daptomycin (P = 0.008) and linezolid (P = 0.02) were used more often as second-line therapy. No significant differences were found in outcomes except LOS (P = 0.05), and hospitalization costs (P = 0.004) were higher with linezolid; antibiotic costs were higher for linezolid (P = 0.001) and daptomycin (P = 0.03). Response rates were similar for the study drugs, although daptomycin and linezolid were used as second-line therapy and associated with higher drug costs.",
author = "Hermsen, {Elizabeth D.} and Shull, {Sara S.} and Mitropoulos, {Isaac F.} and Puumala, {Susan E.} and Rupp, {Mark Edmund}",
year = "2009",
month = "1",
day = "1",
doi = "10.1097/IPC.0b013e318184d74e",
language = "English (US)",
volume = "17",
pages = "17--21",
journal = "Infectious Diseases in Clinical Practice",
issn = "1056-9103",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Prospective evaluation of clinical and economic outcomes associated with treatment of serious infections due to gram-positive cocci

AU - Hermsen, Elizabeth D.

AU - Shull, Sara S.

AU - Mitropoulos, Isaac F.

AU - Puumala, Susan E.

AU - Rupp, Mark Edmund

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Comparative data are needed to define the use of agents to treat serious gram-positive cocci infections. This prospective, open-label, observational cohort study included adults receiving daptomycin, linezolid, vancomycin, or oxacillin/cefazolin for complicated skin and skin structure infections, bacteremia, endocarditis, or osteomyelitis. Primary outcome was clinical response at 180 days. Secondary outcomes included response at the end of therapy, antibiotic switch due to failure, length of stay (LOS), LOS after antibiotic start, mortality, infection-related readmission, and antibiotic and hospitalization costs. One hundred seventeen patients were evaluated for complicated skin and skin structure infections (n= 37), bacteremia (n = 49), endocarditis (n = 10), and osteomyelitis (n = 21). Daptomycin (P = 0.008) and linezolid (P = 0.02) were used more often as second-line therapy. No significant differences were found in outcomes except LOS (P = 0.05), and hospitalization costs (P = 0.004) were higher with linezolid; antibiotic costs were higher for linezolid (P = 0.001) and daptomycin (P = 0.03). Response rates were similar for the study drugs, although daptomycin and linezolid were used as second-line therapy and associated with higher drug costs.

AB - Comparative data are needed to define the use of agents to treat serious gram-positive cocci infections. This prospective, open-label, observational cohort study included adults receiving daptomycin, linezolid, vancomycin, or oxacillin/cefazolin for complicated skin and skin structure infections, bacteremia, endocarditis, or osteomyelitis. Primary outcome was clinical response at 180 days. Secondary outcomes included response at the end of therapy, antibiotic switch due to failure, length of stay (LOS), LOS after antibiotic start, mortality, infection-related readmission, and antibiotic and hospitalization costs. One hundred seventeen patients were evaluated for complicated skin and skin structure infections (n= 37), bacteremia (n = 49), endocarditis (n = 10), and osteomyelitis (n = 21). Daptomycin (P = 0.008) and linezolid (P = 0.02) were used more often as second-line therapy. No significant differences were found in outcomes except LOS (P = 0.05), and hospitalization costs (P = 0.004) were higher with linezolid; antibiotic costs were higher for linezolid (P = 0.001) and daptomycin (P = 0.03). Response rates were similar for the study drugs, although daptomycin and linezolid were used as second-line therapy and associated with higher drug costs.

UR - http://www.scopus.com/inward/record.url?scp=68049098205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049098205&partnerID=8YFLogxK

U2 - 10.1097/IPC.0b013e318184d74e

DO - 10.1097/IPC.0b013e318184d74e

M3 - Article

VL - 17

SP - 17

EP - 21

JO - Infectious Diseases in Clinical Practice

JF - Infectious Diseases in Clinical Practice

SN - 1056-9103

IS - 1

ER -